Avadel Pharmaceuticals PLC Asset Resilience Ratio
Avadel Pharmaceuticals PLC asset resilience ratio. Avadel Pharmaceuticals PLC (AVDL) has an Asset Resilience Ratio of 5.90% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Avadel Pharmaceuticals PLC for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Avadel Pharmaceuticals PLC (2003–2024)
Asset resilience ratio of Avadel Pharmaceuticals PLC from 2003 to 2024. This chart shows how Avadel Pharmaceuticals PLC's Asset Resilience Ratio has changed over time. See AVDL free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Avadel Pharmaceuticals PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see AVDL total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $11.76 Million | 5.9% |
| Total Liquid Assets | $11.76 Million | 5.90% |
Asset Resilience Insights
- Limited Liquidity: Avadel Pharmaceuticals PLC maintains only 5.90% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Avadel Pharmaceuticals PLC Industry Peers by Asset Resilience Ratio
Compare Avadel Pharmaceuticals PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Avadel Pharmaceuticals PLC Asset Resilience Ratio by Year (2003–2024)
Avadel Pharmaceuticals PLC asset resilience ratio by year from 2003 to 2024. The table below shows the annual Asset Resilience Ratio data for Avadel Pharmaceuticals PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 13.64% | $22.41 Million | $164.24 Million | -31.25pp |
| 2023-12-31 | 44.90% | $73.94 Million | $164.70 Million | +27.94pp |
| 2022-12-31 | 16.96% | $22.52 Million | $132.78 Million | -26.12pp |
| 2021-12-31 | 43.08% | $106.51 Million | $247.26 Million | -4.95pp |
| 2020-12-31 | 48.03% | $149.68 Million | $311.64 Million | +12.12pp |
| 2019-12-31 | 35.91% | $54.38 Million | $151.44 Million | -11.69pp |
| 2018-12-31 | 47.60% | $90.59 Million | $190.30 Million | +16.86pp |
| 2017-12-31 | 30.75% | $77.51 Million | $252.11 Million | -16.09pp |
| 2016-12-31 | 46.84% | $114.98 Million | $245.48 Million | +9.75pp |
| 2015-12-31 | 37.09% | $79.74 Million | $214.98 Million | +6.63pp |
| 2014-12-31 | 30.47% | $53.07 Million | $174.21 Million | +30.12pp |
| 2013-12-31 | 0.34% | $401.00K | $116.25 Million | -5.12pp |
| 2012-12-31 | 5.47% | $6.41 Million | $117.31 Million | -24.84pp |
| 2011-12-31 | 30.31% | $21.04 Million | $69.40 Million | -0.73pp |
| 2010-12-31 | 31.04% | $23.16 Million | $74.61 Million | -6.45pp |
| 2009-12-31 | 37.49% | $35.35 Million | $94.30 Million | +26.54pp |
| 2008-12-31 | 10.95% | $10.06 Million | $91.86 Million | -3.60pp |
| 2007-12-31 | 14.55% | $14.75 Million | $101.40 Million | +5.02pp |
| 2006-12-31 | 9.53% | $10.94 Million | $114.89 Million | -57.03pp |
| 2005-12-31 | 66.55% | $82.76 Million | $124.35 Million | -2.66pp |
| 2004-12-31 | 69.22% | $100.78 Million | $145.61 Million | -15.98pp |
| 2003-12-31 | 85.20% | $108.42 Million | $127.25 Million | -- |
About Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name… Read more